Utzschneider, Kristina M.Tripputi, Mark T.Kozedub, AlexandraBarengolts, ElenaCaprio, SoniaCree-Green, MelanieEdelstein, Sharon L.El Ghormli, LaureHannon, Tamara S.Mather, Kieren J.Palmer, JerryNadeau, Kristen J.RISE Consortium2023-08-152023-08-152021Utzschneider KM, Tripputi MT, Kozedub A, et al. Differential loss of β-cell function in youth vs. adults following treatment withdrawal in the Restoring Insulin Secretion (RISE) study. Diabetes Res Clin Pract. 2021;178:108948. doi:10.1016/j.diabres.2021.108948https://hdl.handle.net/1805/34917Aims: To compare OGTT-derived estimates of β-cell function between youth and adults with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes after treatment discontinuation in RISE. Methods: Youth (n = 89) and adults (n = 132) were randomized to 3 months glargine followed by 9 months metformin (G/M) or 12 months metformin (MET). Insulin sensitivity and β-cell responses were estimated from 3-hour OGTTs over 21 months. Linear mixed models tested for differences by time and age group within each treatment arm. Results: After treatment withdrawal, HbA1c increased in both youth and adults with a larger net increase in G/M youth vs. adults at 21 months. Among youth, β-cell function decreased starting at 12 months in G/M and 15 months in MET. Among adults, β-cell function remained relatively stable although insulin secretion rates decreased in G/M at 21 months. At 21 months vs. baseline β-cell function declined to a greater extent in youth vs. adults in both the G/M and MET treatment arms. Conclusions: After treatment withdrawal youth demonstrated progressive decline in β-cell function after stopping treatment with either G/M or MET. In contrast, β-cell function in adults remained stable despite an increase in HbA1c over time.en-USPublisher Policyβ-cell functionImpaired glucose toleranceInsulin secretionType 2 diabetesYouthMetforminArticle